

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Cauwenberghs *et al.*                      CONFIRMATION NO.: 7478  
APPLICATION NO.: 10/019,740                      GROUP NO.: 1641  
FILING DATE: May 8, 2002                      EXAMINER: Jung, Unsu

TITLE: Detection of von-Willebrand Factor (vWF) Activity

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SECOND DECLARATION OF DR. HANS DECKMYN**  
**UNDER 37 C.F.R. § 1.132**

Dear Sir:

I, Dr. Hans Deckmyn, hereby declare and state as follows:

1. I am a recognized expert in the field of von Willebrand's disease and have been working in this field for many years. My *curriculum vitae*, which includes my educational and employment history and a list of my publications and patents, is attached hereto as Exhibit A. My present position is Professor of Chemistry at KU Leuven Campus Kortrijk. I am also a board member of the Belgian Society on Thrombosis and Haemostasis and an executive officer of the European Thrombosis Research Organization.
2. I am a co-inventor of the subject matter claimed in U.S. Patent Application No. 10/019,740, ("the present application"). I understand that the earliest effective filing date of the present application is July 5, 1999. I am also familiar with the November 17, 2008, Office action as well as the Favaloro, Hoylaerts, and Vischer articles, and the Handin U.S. patent cited therein.
3. von Willebrand's disease (vWD) is a common inherited bleeding disorder associated with defects in von Willebrand factor (vWF), a protein required for platelet adhesion. Type 1 and Type 3 vWD are the result of quantitative defects in vWF production. For example,

Type 1 vWD is characterized by reduced plasma concentrations of vWF as compared to normal, while Type 3 vWD is characterized by negligible to absent vWF concentrations. Type 2 vWD is caused by qualitative defects in vWF, *i.e.*, vWF is functionally abnormal. There are 4 known subtypes of type 2 vWD: 2A, 2B, 2M, and 2N.

4. As of the earliest effective filing date of this application, it was understood by those skilled in the art of vWD that high molecular weight (HMW) multimers of vWF are responsible for inducing platelet aggregation. It was understood that such platelet aggregation is induced when HMW multimers of vWF bind to GP1b receptors on platelets. Further it was understood that multimerization of vWF monomers is necessary for bioactivity of vWF.
5. As of the earliest effective filing date of this application, it was understood by those skilled in the art that each of Type 2A vWD and Type 2B vWD are characterized by the absence of HMW multimers of vWF. In Type 2A vWD patients, the absence of HMW vWF multimers is attributable to errors in protein synthesis that interfere with multimer assembly and/or increased sensitivity of vWF to proteases. As a result, Type 2A patients produce only small fragments or monomers of vWF that cannot multimerize. Consequently, the vWF produced by Type 2A patients has a decreased capacity to interact with platelet GP1b receptor.
6. In contrast, as of the earliest effective filing date of this application, Type 2B vWD was known in the art to be characterized by increased affinity of Type 2B vWF for platelet GP1b. This was known to be the result of a genetic defect that increases the binding affinity of Type 2B vWF for the GP1b receptor. As a result, Type 2B vWF binds to platelet GP1b in circulating blood. Upon binding of vWF to the circulating platelets, platelets aggregate and are cleared from the blood. This accounts for the absence of free (unbound to platelet GP1b) high molecular weight vWF multimers in Type 2B patients. In contrast to Type 2B vWF, normal vWF does not spontaneously interact with the GP1b receptor unless vWF is activated as the result of a bleeding injury.
7. If blood, plasma, or serum from a Type 2B patient sample were incubated with ristocetin and isolated GP1b, a skilled artisan, as of the earliest effective filing date, would have expected to detect only low amounts of vWF binding to isolated GP1b. This is due to the

fact that the HMW vWF multimers would already be bound to GP1b receptors on the patient's own platelets. However, some minimal binding from vWF monomers would contribute to the low amount of vWF binding detected.

8. If blood, plasma, or serum from a Type 2A patient sample were incubated with ristocetin and isolated GP1b, a skilled artisan, as of the earliest effective filing date, would have expected to detect only low amounts of vWF binding to isolated GP1b due to the absence of HMW vWF multimers in the patient sample. However, some minimal binding from vWF monomers would contribute to the low amount of vWF binding. The low level of binding detected between Type 2A vWF and GP1b in the presence of ristocetin discussed here in paragraph 8 would be expected to be the same as the low level of binding detected between Type 2B vWF and GP1b in the presence of ristocetin as discussed in paragraph 7.
9. Based on my statements in paragraphs 4-8 above, as of the earliest effective filing date, a skilled artisan assaying Type 2A or Type 2B patient samples in the presence of ristocetin and isolated GP1b would have expected the results from each assay to exhibit the same level of vWF binding, *i.e.*, a low amount, due to the absence of HMW vWF multimers necessary for binding to GP1b.
10. As of the earliest effective filing date, persons of skill in the art were aware that Type 2A vWD and Type 2B vWD could be distinguished from one another because platelets from a Type 2B patient will aggregate in response to low concentrations of ristocetin, while platelets from a Type 2A patient will not. The difference between platelet aggregation patterns between Type 2A and Type 2B are observed only when patient platelets are assayed and not when exogenous platelets, *i.e.*, non-patient platelets, are assayed in the presence of ristocetin. This assay using patient platelets is known as a ristocetin-induced platelet aggregation (RIPA) assay. The aggregation of Type 2B platelets at low concentrations of ristocetin observed in the RIPA assay is a result of the high affinity for platelet GP1b exhibited by vWF from Type 2B patients. Because of the high affinity for platelet GP1b, Type 2B vWF does not require the same level of cofactor assistance from ristocetin to bind to GP1b as required by normal vWF. In contrast, platelets from a Type 2A vWD patient will exhibit no or a little aggregation in the presence of low or high

concentrations of ristocetin because Type 2A vWF contains only small vWF monomers which have a low affinity for GP1b, binding to which is necessary to cause platelet aggregation.

11. Based on my statements in paragraphs 4-10, if ristocetin and an isolated GP1b fragment were used in an assay with a patient sample containing patient platelets (patient platelets being required by a RIPA assay), the isolated GP1b would compete with platelet GP1b of patient platelets for binding to defective Type 2B vWF. Given that some defective Type 2B vWF would bind to platelet GP1b and some to isolated GP1b, this would interfere with the results by reducing the expected amount of agglutination. Further, reduced levels of agglutination would also be seen with patient platelets from a Type 2A vWD patient. Because of the reduced levels of agglutination from the expected levels needed to distinguish between Type 2A and Type 2B vWD, it would not be possible to accurately distinguish type 2A and Type 2B vWD from one another employing such a method.
12. As an inventor of the invention presently claimed in this application, I believe that I and the other inventors were the first to recognize the utility of GP1b $\alpha$  isolated from a platelet, as opposed to using whole platelets, in an assay for detecting vWF ristocetin cofactor activity, that is the binding activity of vWF to GP1b $\alpha$  (or a fragment thereof) in the presence of ristocetin or a functionally equivalent substance.
13. In the process of developing a method for discriminating between different types of von Willebrand disease using a vWF binding activity, I and the other inventors first determined whether the binding activity of normal vWF to soluble forms or portions of GP1b $\alpha$  could be adequately detected in the presence of ristocetin by immobilizing the soluble forms or portions of GP1b $\alpha$  to plastic, for example, to 96 well plastic plates, and would therefore be useful for a clinical assay for detecting vWF binding activity in the presence of ristocetin. We assayed both glycocalicin, a naturally occurring soluble fragment of GP1b $\alpha$ , and a recombinant fragment of GP1b $\alpha$ , GP1b $\alpha$ <sub>(1-289)</sub>, for their ability to bind to vWF in the presence of ristocetin. For each GP1b $\alpha$  fragment immobilized to plastic that we tested, we determined that the binding activity of normal vWF in the presence of ristocetin was negligible and therefore not useful for a clinical assay for

detecting vWF binding to GP1b $\alpha$  in the presence of ristocetin. We determined that vWF was unable to bind the immobilized GP1b $\alpha$  fragments because immobilization of the GP1b $\alpha$  fragments causes a conformational change in GP1b $\alpha$ , thereby preventing vWF binding to the GP1b $\alpha$  fragments. Accordingly, we concluded that assaying vWF binding activity to GP1b $\alpha$  or a fragment thereof immobilized to plastic in the presence of ristocetin would not be an effective substitute for detecting vWF ristocetin cofactor activity in the presence of platelet-GP1b because the plastic-immobilized GP1b $\alpha$  fragments did not permit detection of any significant vWF binding activity.

14. Given that immobilizing GP1b $\alpha$  fragments was not successful, we sought other means for utilizing GP1b $\alpha$  fragments in a clinical assay for detecting vWF binding activity in the presence of ristocetin. Subsequently, we discovered that in order to detect the binding activity of vWF to GP1b $\alpha$  or a fragment thereof, it is necessary to present the soluble form or portion of GP1b $\alpha$  by an anti-GP1b $\alpha$  antibody. Over 90 monoclonal antibodies against GP1b $\alpha$  were screened in order to detect anti-GP1b $\alpha$  antibodies, that when bound to GP1b $\alpha$ <sub>(1-289)</sub>, permitted binding of GP1b $\alpha$  to vWF. Over 40 monoclonal anti-GP1b $\alpha$  antibodies were screened in order to detect anti-GP1b $\alpha$  antibodies, that when bound to glycocalicin, permitted binding of glycocalicin to vWF. Anti-GP1b $\alpha$  antibodies were coated on plastic well plates and glycocalicin or a GP1b $\alpha$  fragment were added to the plate. After incubation, normal vWF and ristocetin were added. Binding between vWF and the GP1b $\alpha$ <sub>(1-289)</sub> fragment or glycocalicin was detected by using an anti-vWF antibody labeled with horseradish peroxidase according to standard ELISA techniques. For 3 anti-GP1b $\alpha$  antibodies, we detected sufficient levels of vWF binding to the GP1b $\alpha$  fragment in the presence of ristocetin. For 1 anti-GP1b $\alpha$  antibody, we detected sufficient levels of vWF binding to glycocalicin in the presence of ristocetin. Accordingly, we determined that these anti-GP1b $\alpha$  antibodies would be suitable for presenting GP1b $\alpha$  in an assay for detecting vWF binding to GP1b $\alpha$  or a fragment thereof in the presence of ristocetin.
15. I further declare that all statements made in this Declaration are of my own knowledge, are true, and that all statements made on information and belief are believed to be true. Moreover, these statements were made with the knowledge that willful false statements

and the like made by me are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated:

May 15, 2009

By:

Hans Deckmyn

Dr. Hans Deckmyn

## Curriculum Vitae Hans DECKMYN

**Office address:** Laboratory for Thrombosis Research  
KU Leuven Campus Kortrijk, E. Sabbelaan 53 B-8500 Kortrijk  
(Belgium)  
tel.: 32-56.246.171 (office), .422 (lab), fax: 32-56.246.997  
e-mail: [Hans.Deckmyn@kuleuven-kortrijk.be](mailto:Hans.Deckmyn@kuleuven-kortrijk.be)  
<http://www.kuleuven-kortrijk.be/irc/trombose>

### Professional positions

1977-1980: Doctoral student Laboratory for Biochemistry (G.Préaux)  
1981-1985: Postdoc Center for Thrombosis and Vascular Research, (M. Verstraete, J. Vermynen)  
1985-1987: Postdoc Hematology-Oncology, Washington U, School Medicine, St. Louis Mo (P.W. Majerus),  
1988-1992: Senior Researcher Center for Molecular & Vascular Biology KU Leuven (D. Collen, J. Vermynen)  
1992-1996: Associate Professor in Chemistry KU Leuven Campus Kortrijk  
1994-present: Head of the Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk  
1996-1999: Professor in Chemistry KU Leuven Campus Kortrijk  
1999-present: Full Professor in Chemistry KU Leuven Campus Kortrijk

### Other

1992-1998: Associate Editor "*Thrombosis and Haemostasis*".  
1994-1998: Editorial Advisor "*The Biochemical Journal*".  
96-02,08-09: Member Research Council KU Leuven  
1998-2004: Editor "*The Biochemical Journal*".  
1999-2002: Member Advisory Board "*Thrombosis and Haemostasis*".  
2000-2006: Chairman Interdisciplinary Research Center (IRC), KU Leuven Campus Kortrijk  
2000-2006 Member Board 'Innovation & Incubation Center Kortrijk' (IICK)  
2001-2002 Vice-chairman Advisory Council on Innovation Charter Zuid-West-Vlaanderen  
2001-2006 Member Board 'Researchpark Hoog Kortrijk'  
2002-present Member Advisory Board "*Journal of Thrombosis and Haemostasis*".  
2002-present Member Board 'Belgian Society on Thrombosis and Haemostasis' (BSTH)  
2003-present Member Steering committee 'CIS Innovation West-Vlaanderen'  
2004-present Spokesman "Interfaculty Center for Biomacromolecular Structure Research" (BioMacS)  
KU Leuven <http://biomacs.kuleuven.be/index.htm>  
2005-present Board member 'European Cardiovascular Genetics Institute' (ECGI)  
2005-2007 Member Council for Industrial Research KU Leuven  
2006-2008 Section Editor '*Thrombosis and Haemostasis*'  
2006-present Member FWO commission Molecular & Cellular Biology, Genetics

2007-present Executive Officer 'European Thrombosis Research Organisation'  
(ETRO)  
2007-present Founding member PharmAbs <http://www.pharmabs.org/>

## Various

## Honors and awards

---

1978-1979: Fellowship IWONL (Institute for Advancement of Sc.Res. in Industry & Agriculture, Belgium)  
1985: Prize Boehringer-Ingelheim for Research on Thrombosis and Coagulation  
1985-1987: NATO Research Fellowship  
1985-1986: Fulbright Research Award  
1989: Young Investigator Award XIIth Congress on Thrombosis and Haemostasis  
1991 Prize "Dr. en Mevr. Schamelhout-Koettlitz "-Foundation for Scientific Research (Royal Academy of Medicine of Belgium)  
1992 Fellowship "Belgian Action against Cancer"  
1993 Triannual Prize Baron Simonart Foundation for Clinical Pharmacological Research  
1995 Research grant O.Dupont Foundation (Royal Academy of Medicine of Belgium)  
1997 Visiting professor "Pro Renovanda" University of Debrecen, Hongarije, Medical School  
2004 Triannual price *Sidmar* for 'Medical Scientific Research' (Royal Academy for Medicine)  
2009 Doctor Honoris Causa, University of Debrecen, Hungary

## Memberships, meetings, journals

---

1. *International Society on Thrombosis and Haemostasis* (ISTH)
  - 1992-present: Member
  - 1992-8: Associate Editor Journal of the Society: "*Thrombosis and Haemostasis*"
  - 1999-2001: Member Advisory Board "*Thrombosis and Haemostasis*".
  - 2002-present: Member Advisory Board "*Journal on Thrombosis and Haemostasis*".
2. *Biochemical Society*
  - 1994-present: member
  - 1994-1998: Editorial Advisor of "*The Biochemical Journal*"
  - 1998-2003: Co-Editor of "*The Biochemical Journal*"
3. *European Thrombosis Research Organisation* (ETRO)
  - 1995-present: Laboratory for Thrombosis Research, IRC-KULAK elected member
  - 1997, 2003 Invited speaker ETRO Advanced Teaching Course, Heviz, H; Blankenberge, B



- 2007-10: Executive Officer & webmaster  
 4. *Belgian Society on Thrombosis and Haemostasis (BSTH)*  
 1993-present member  
 2002-present member of the board & webmaster  
 5. *Koninklijke Vlaams Chemische Vereniging*  
 1998- present: member

Member Scientific Committee *European Platelet and Granulocyte Immunobiology Symposium*

(Bamberg, D 1992, Cambridge, UK 1994, Hammeenlinna, SF 1996, S'Agaro, E, 1998, Amsterdam, NL, 2000, Lago Maggiore, I, 2002, Rust A, 2004, Tromso, N, 2006, Thun, CH, 2008, Beaune, FR 2010)

## Teaching

- 1992-present: Introductory course 'General Chemistry': 1<sup>st</sup> yr Medicine, Biomedical Sciences,  
 Biochemistry, Biology, Chemistry, Physics,  
 Mathematics, Bio-engineers, Pharmacy  
 1992-2003: Chemistry II (Systematics) 1<sup>st</sup> yr Biochemistry, Chemistry, Biology  
 1996-2000: Mechanisms of signal transduction, PhD-training Sci-Bioengin-  
 Pharmacy-Biomedic Sciences  
 1999-present: Cell Biology (part signal Transduction) : 1<sup>st</sup> yr Medicine, Biomedical Sciences  
 2005-present: Biochemistry: 1<sup>st</sup> yr Biochemistry, Chemistry, Biology, Bioengineers, Pharmacy  
 Since 2003: promotor 7 PhD thesises, 5 in preparation

## International Advisory functions

1. 1996-present: Dutch "*Nederlandse Hartstichting*"
2. 1997, 2001: Austrian "*Fonds zur Förderung der wissenschaftlichen Forschung*"
3. 1998-present: British "*Medical Research Council*"
4. 1998: South-African "*Medical Research Council*"
5. 1999: *EU-projects* External Expert
6. 99,00, 04: Luxembourg "*Ministère de la Culture, de l'Enseignement Supérieur et de la Recherche*"
7. 2000: Dutch "*Nederlandse Organisatie voor Wetenschappelijk Onderzoek*"
8. 2003: British "*Wellcome Foundation*"
9. 2004: Irish "*Science Foundation*" (SFI)
10. 2004-present French *AERES* (INSERM)

11. 2004: Irish "Research Funding and Policy Division, Health Research Board (HRB)"
12. 2004, 2007 : Luxembourg "Centre de recherche Public de la Santé"
13. 2006, 2007: French 'Agence Nationale de la Recherche -ANR' Research on rare diseases
14. 2006: Irish "Health Research Board" (HRB)
15. 2006: U of Cambridge UK "Promotions Committee for the Faculty of Biology"
16. 2007-present: French "Agence Nationale de la Recherche-ANR" 'Pathophysiology of Human Diseases'

At present our research group consists of 2 professors, 4 postdocs, 4 PhD-students and 4 technicians.

The yearly budget (incl. salaries) amounts to ~€ 860.000, all from competitive grants.

---

## Scientific output

### Publications

---

- 175 publications (Medline), 4,806 citations, h-index: 33 (ISI)  
of which 1 in Science (26.372), 2 in Circulation (12.755), 24 in Blood ( IF 10.896),  
7 in ATVB (7.221), 5 in J Thromb Haemost (5.947), 8 in J Biol Chem (5.581),
- 14 chapters in books

### Patents

---

#### Granted

1. CELL LINES, LIGANDS AND ANTIBODY FRAGMENTS FOR USE IN PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING HAEMOSTASIS DISORDERS

European patent granted 2007/01/31, US patent granted

Inventors: N. Cauwenberghs, H. Deckmyn

2. "Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial thrombus formation in baboons.

European patent granted 4/2008

Inventors : K. Vanhoorelbeke, N. Cauwenberghs, H. Deckmyn

#### Pending

1. "Detection of von-Willebrand factor (vWF) activity"

EP patent Application, Inventors: N. Cauwenberghs, K. Vanhoorelbeke, H. Deckmyn

### Licenses

---

A new diagnostic test to determine the quality of von Willebrand Factor, with clearly better reproducibility and sensitivity than the test currently used in the clinic (see patent application and Vanhoorelbeke et al Thromb Haemost. 2000;83:107-13) outlicensed to Instrumentation Laboratories (NJ) and further developed by Biokit (Barcelona). Beta version tested and approved.

#### **Current research interests**

1. Development of platelet adhesion inhibitors by interfering with the collagen-VWF-platelet GPIIb axis as new antithrombotics with a lower bleeding risk, for treatment of e.g. ischemic stroke or TTP
2. Functional genomics in blood platelets (production and characterisation of platelets from genetically manipulated (silencing/overexpressing) hematopoietic stem cells transplanted in irradiated mice)

# **Publication list Hans Deckmyn**

1. Defreyn G, Deckmyn H, Vermynen J.  
A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2.  
**Thromb. Res.** 26, 389-400, 1982
2. Badenhorst PN, Deckmyn H, Vermynen J.  
The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man.  
**Thromb. Res.** 28, 59-66, 1982.

---

3. Boogaerts MA, Vermynen J, Deckmyn H, Roelant C, Verwilghen RL, Jacobs HS, Moldow CF.  
Enkephalins modify granulocyte-endothelial interactions by stimulating prostacyclin production.  
**Thromb. Haemost.** 50, 572-575, 1983.
4. Deckmyn H, Proesmans W, Vermynen J.  
Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure.  
**Thromb. Res.** 30, 13-18, 1983.
5. Spitz B, Deckmyn H, Van Assche FA, Vermynen J.  
Prostacyclin production in whole blood throughout normal pregnancy.  
**Clin.Exp.Hypert.-Hypert. in Pregnancy** B2, 191-202, 1983.
6. Vermynen J, Badenhorst PN, Deckmyn H, Arnout J.  
Normal mechanisms of platelet function.  
**Clin. Haematol.** 12, 107-151, 1983.
7. Vermynen J, Deckmyn H.  
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.  
**Br.J.Clin.Pharmacol.** 15, 17S-22S, 1983.
8. Deckmyn H, Font L, Van Hemelen C, Carreras LO, Defreyn G, Vermynen J.  
Low prostacyclin synthetase activity of fetal rat aorta.  
**Life Sci.** 33, 1491-1497, 1983.
9. Deckmyn H, Van Houtte E, Verstraete M, Vermynen J.  
Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom.  
**Biochem. Pharmacol.** 32, 2757-2762, 1983.
10. Gresele P, Zoja C, Deckmyn H, Arnout J, Vermynen J, Verstraete M.  
Dipyridamole inhibits platelet aggregation in whole blood.  
**Thromb. Haemost.** 50, 852-856, 1983.

---

11. Van Assche FA, Spitz B, Vermynen J, Deckmyn H.  
Preliminary observations on treatment of pregnancy induced hypertension with a thromboxane synthetase inhibitor.  
**Am. J. Obstet. Gynecol.** 148, 216-218, 1984.
12. Boogaerts MA, Van de Broeck J, Deckmyn H, Roelant C, Vermynen J, Verwilghen RL. Protective effect of vitamin E on immune triggered granulocyte mediated endothelial injury.

**Thromb. Haemost.** 51, 89-92, 1984.

13. Deckmyn H, Gresele P, Arnout J, Vermynen J.  
BM 13.177 specifically blocks the platelet thromboxane receptor.  
**Arch. Intern. Pharmacodynam. Ther.** 268, 165-166, 1984.
  14. Essien EM, Arnout J, Deckmyn H, Vermynen J, Verstraete M.  
Blood changes and enhanced thromboxane and 6-keto prostaglandin F<sub>1</sub> $\alpha$  production in experimental acute plasmodium bergi infection in hamsters.  
**Thromb. Haemost.** 51, 362-365, 1984.
  15. Gresele P, Deckmyn H, Arnout J, Vermynen J.  
Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer.  
**Br. J. Haemat.** 57, 171-173, 1984.
  16. Gresele P, Deckmyn H, Huybrechts E, Vermynen J.  
Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D<sub>2</sub>.  
**Biochem. Pharmacol.** 33, 2083-2088, 1984.
  17. Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermynen J.  
BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.  
**Lancet** i, 991-994, 1984.
  18. Deckmyn H, Gresele P, Arnout J, Todisco A, Vermynen J.  
Prolonging prostacyclin production by nafazatrom and dipyridamole.  
**Lancet** ii, 410-411, 1984.
  19. Spitz B, Deckmyn H, Van Assche FA, Vermynen J.  
Prostacyclin in pregnancy.  
**Eur. J. Obstet. Reprod. Biol.** 18, 303-308, 1984.
- 
20. Arnout J, Vanrusselt M, Deckmyn H, Vermynen J, Fiocchi R, Lijnen P, Amery A.  
Platelet hypersensitivity to serotonin after prolonged ketanserin intake?  
**J. Cardiovasc. Pharmacol.** 7 (suppl.7), S20-S22, 1985.
  21. Ceuppens JL, Vertessen S, Deckmyn H, Vermynen J.  
Effects of thromboxane A<sub>2</sub> on lymphocyte proliferation.  
**Cell. Immunol.** 90, 458-463, 1985.
  22. De Maeyer P, Deckmyn H, Arnout J, Vermynen J.  
Intravenous ionic contrast media cause local prostacyclin release in man  
**Investigative Radiol.** 20, 458-463, 1985.
  23. Deckmyn H, Zoja C, Arnout J, Todisco A, D'Hondt J, Vanden Bulcke F, Hendrickx N, Gresele P, Vermynen J.  
Partial isolation and function of the prostacyclin regulating plasma factor.  
**Clin. Sc.** 69, 383-393, 1985.
  24. Gresele P, Arnout J, Deckmyn H, Vermynen J.  
Combining antiplatelet agents: potentiation between aspirin and dipyridamole.  
**Lancet** i, 937-938, 1985.
  25. Gresele P, Bounameaux H, Arnout J, Perez-Requejo JL, Deckmyn H, Vermynen J.

Thromboxane A<sub>2</sub> and prostacyclin do not modulate the systemic hemodynamic response to cold in humans.

**J. Lab. Clin. Med.** 106, 534-541, 1985.

26. Janssens WJ, Deckmyn H, Gresele P, Vermynen J.  
BM 13.177 selectively inhibits endoperoxide analog induced vascular contractions.  
**Arch. Int'l Pharmacodyn. Ther.** 276, 28-34, 1985.
  27. Spitz B, Deckmyn H, Van Bree R, Pijnenborg R, Vermynen J, Van Assche FA.  
Influence of a vitamin E deficient diet on prostacyclin production by mesometrial triangles and aortic rings from non-diabetic and diabetic rats.  
**Am. J. Obstet. Gynecol.** 151, 116-120, 1985.
  28. Van Renterghem Y, Roels L, Lerut T, Gruwez J, Michielsens P, Gresele P, Deckmyn H, Colucci M, Arnout J, Vermynen J.  
Thrombo-embolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney transplants.  
**Lancet** i, 999-1002, 1985.
  29. Gresele P, Deckmyn H, Arnout J, Zoja C, Vermynen J.  
Lack of synergism between dazoxiben and dipyridamole following administration to man.  
**Thromb. Res.** 37, 231-236, 1985.
  30. Vermynen J, Deckmyn H, Arnout J, Gresele P.  
A. Schmidt Memorial Lecture: Peroxides in haemostasis and thrombosis.  
**Haemostasis** 15, 8-9, 1985.
  31. Vervliet G, Deckmyn H, Carton H, Billiau A.  
Influence of prostaglandin E<sub>2</sub> and indomethacin on interferon-gamma production by cultured peripheral blood leukocytes of multiple sclerosis patients and healthy donors.  
**J. Clin. Immunol.** 5, 102-108, 1985.
- 
32. Gresele P, Arnout J, Deckmyn H, Vermynen J.  
Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.  
**Thromb. Haemost.** 55, 12-18, 1986.
  33. Vermynen J, Arnout J, Deckmyn H, Xhonneux B, De Clerck F.  
Continuous inhibition of the platelet S<sub>2</sub>-serotonergic receptors during the long term administration of ketanserin.  
**Thromb. Res.** 42, 721-723, 1986.
  34. Vermynen J, Blockmans D, Spitz B, Deckmyn H.  
Thrombosis and immune disorders.  
**Clin. Haematol.** 15, 393-412, 1986.
  35. Gresele P, Arnout J, Coene MC, Deckmyn H, Vermynen J.  
Leukotriene B<sub>4</sub> production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells.  
**Biochem. Biophys. Res. Commun.** 137, 334-342, 1986.
  36. Majerus PW, Connolly TM, Deckmyn H, Ross TS, Bross TE, Ishii H, Bansal V, Wilson DB. The production of phosphoinositide-derived messenger molecules.  
**Science** 234, 1519-1526, 1986.

37. Deckmyn H, Tu SM, Majerus PW.  
Guanine nucleotides stimulate soluble phospholipase C in the absence of membranes.  
**J. Biol. Chem.** 261, 16553-16558, 1986.
38. Ceuppens JL, Robaeys G, Verdickt W, Vertessen S, Deckmyn H, Dequeker J.  
Immunomodulatory effects of non-steroidal anti-inflammatory agents in vivo on lymphocyte function in vitro.  
**Arthritis Rheumat.** 29, 305-311, 1986.
39. Kienast J, Arnout J, Deckmyn H, Pfliegler G, Hoet B, Vermynen J.  
On the role of guanine nucleotide binding regulatory proteins (G-proteins) in signal transduction in human platelets: studies with sodium fluoride (NaF).  
**Agents Actions**, Suppl. 20, 175-180, 1986.

---

40. Kienast J, Arnout J, Pfliegler G, Deckmyn H, Hoet B, Vermynen J.  
Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity.  
**Blood** 69, 859-866, 1987.
41. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermynen J.  
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.  
**J. Clin. Invest.** 80, 1435-1445, 1987.
42. Arnout J, Kienast J, Deckmyn H, Vermynen J.  
Prostacyclin stimulatory activity of reducing cofactors in human plasma filtrate. A potential role for uric acid.  
**Agents and Actions** 22, 360-361, 1987.
43. Gresele P, Arnout J, Deckmyn H, Vermynen J.  
L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB<sub>4</sub>-production by stimulated human polymorphonuclear cells but not by stimulated whole blood.  
**Biochem. Pharmacol.** 36, 3529-3532, 1987.
44. Arnout J, Van Russelt M, Deckmyn H, Vermynen J.  
Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.  
**Haemostasis** 17, 344-348, 1987.

---

45. Gresele P, Blockmans D, Deckmyn H, Vermynen J.  
Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and non-responders.  
**J Pharmacol. Exp. Ther.** 246, 301-307, 1988.
46. Falcon C, Pfliegler G, Deckmyn H, Vermynen J.  
The platelet insulin receptor: detection, partial characterization, and search for a function.  
**Biochem. Biophys. Res. Comm.** 157, 1190-1196, 1988.

---

47. Van Geet C, Deckmyn H, Kienast J, Wittevrongel C, Vermynen J.  
Dual effect of fluoride on endothelial prostacyclin production: a phospholipase C mediated phenomenon.  
**Prog. Clin. Biol. Res.** 301, 377-381, 1989.
48. Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermynen J.

Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophthalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A<sub>2</sub> receptor antagonist in human platelets.

**Thromb. Haemost.** 61, 479-484, 1989.

---

49. Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermynen J.  
R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.  
**Blood** 75, 646-653, 1990.
  50. Van Geet C, Deckmyn H, Kienast J, Wittevrongel C, Vermynen J.  
Guanine nucleotide-dependent inhibition of phospholipase C in human endothelial cells.  
**J. Biol. Chem.** 265, 7920-7926, 1990.
  51. Deckmyn H, Chew SL, Vermynen J.  
Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction.  
**Thromb. Haemost.** 64, 74-79, 1990.
  52. Hoet B, Arnout J, Van Geet C, Deckmyn H, Verhaeghe R, Vermynen J.  
Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.  
**Thromb. Haemost.** 64, 87-90, 1990.
  53. Hoet B, Deckmyn H, Arnout J, Vermynen J.  
Pharmacological manipulation of the thromboxane pathway in blood platelets.  
**Blood Coag Fibrinol.** 1, 225-234, 1990.
  54. Kienast J, Arnout J, Deckmyn H, Van der Schueren B, Vermynen J.  
Non-receptor mediated refractoriness in prostacyclin production by human endothelial cells in a continuous flow system is delayed by a low molecular weight plasma fraction devoid of reducing cofactors for peroxide-catalyzed reactions.  
**Blood Coag. Fibrinol.** 1, 609-618, 1990.
- 
55. Stockmans F, Deckmyn H, Gruwez J, Vermynen J, Acland R.  
Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein.  
**Thromb. Haemost.** 65, 425-431, 1991.
  56. Tornai I, Declerck PJ, Smets L, Arnout J, Deckmyn H, Caekebeke-Peerlinck KMJ, Vermynen J.  
Measurement of von Willebrand factor antigen in plasma and platelets with an enzyme-linked immunosorbent assay based on two murine monoclonal antibodies.  
**Haemostasis** 21, 125-134, 1991.
  57. Gresele P, Deckmyn H, Nenci GG, Vermynen J.  
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.  
**TIPS (Trends Pharmacol. Sc.)** 12, 158-163, 1991.
  58. Stockmans F, Deckmyn H, Vermynen J.  
Thrombosis in injured small vessels.  
**Plast. Reconstr. Surg.** 88, 174-175, 1991.
- 
59. Deckmyn H, Van Houtte E, Vermynen J.  
Disturbed platelet aggregation to collagen associated with an antibody against a 85-90 Kd platelet glycoprotein in a patient with prolonged bleeding time.  
**Blood** 79, 1466-1471, 1992.



60. Vermynen J, Deckmyn H.  
Thromboxane synthase inhibitors and receptor antagonists.  
**Cardiovasc. Drugs Ther.** 6,29-33, 1992.

---

61. Deckmyn H, Van Geet C, Vermynen J.  
Dual regulation of phospholipase activity by G-proteins.  
**News Physiol. Sci.** 8,61-63, 1993.
62. Tornai I, Arnout J, Deckmyn H, Peerlinck K, Vermynen J.  
A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein Ib - and IIb/IIIa-binding domains.  
**J. Clin. Invest.** 91, 273-282, 1993.
63. De Reys S, Blom C, Lepoudre B, Declerck PJ, De Ley M, Vermynen J, Deckmyn H.  
Human platelet aggregation by murine monoclonal antibodies is subtype-dependent.  
**Blood** 81, 1792-1800, 1993.
64. Pfliegler G, Arnout J, Kienast J, Wittevrongel C, Hoet B, Deckmyn H, Vermynen J.  
Sodium fluoride induced activation of phospholipase C does not depend on ADP, PAF or arachidonate products.  
**Thromb. Res.** 69, 541-545, 1993.
65. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermynen J, Arnout J. MK-383 (L-700,462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, is active in man.  
**Circulation** 88, 1512-1517, 1993.
66. Hoet B, Arnout J, Deckmyn H, Vermynen J.  
Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.  
**Thromb. Haemost.** 70, 822-825, 1993.
67. Jaspers M, Vekemans S, Carmeliet G, Van Leuven F, De Strooper B, Deckmyn H, Cassiman JJ.  
The  $\alpha$ 2-subunit of VLA-2 and the fibrinogen  $\alpha$ -chain share an RGD-domain recognized by MAB-3H8.  
**Hybridoma** 12, 467-474, 1993.

---

68. Kiss RG, Stassen JM, Deckmyn H, Roskams T, Gold HK, Plow EF, Collen D.  
Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.  
**ArteriosclerThromb** 14, 375-380, 1994
69. De Reys S, Hoylaerts MF, De Ley M, Vermynen J, Deckmyn H.  
Fc-independent cross-linking of a novel platelet membrane protein by a monoclonal antibody causes platelet activation.  
**Blood** ,84, 547-555, 1994
70. Deckmyn H, Stanssens P, Hoet B, Declerck P, Lauwereys M, Gansemans Y, Tornai I, Vermynen J.  
An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR<sub>3</sub> of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function.  
**Brit J Haematol**, 87, 562-571, 1994

71. Matsuno H, Stassen JM, Vermynen J, Deckmyn H  
Inhibition of integrin function by a cyclic RGD-containing peptide, prevents neointima formation.  
**Circulation**, 90, 2203-2206, 1994
  72. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermynen J, Arnout J.  
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men.  
**Clin Pharm Ther**, 56, 377-388, 1994.
  73. Deckmyn H, Zhang J, Van Houtte E, Vermynen J.  
Production and nucleotide sequence of an inhibitory human IgM autoantibody directed against platelet glycoprotein Ia/IIa.  
**Blood**, 84, 1968-1974, 1994
- 
74. Deckmyn H, De Reys S.  
Functional effects of human antiplatelet antibodies.  
**Seminars Thromb. Haemost.**, 21, 46-59, 1995.
  75. Harsfalvi J, Stassen JM, Van Houtte E, Sawyer RT, Vermynen J, Deckmyn H.  
Calin from *Hirudo medicinalis*: an inhibitor of von Willebrand binding to collagen under static and flow conditions.  
**Blood**, 85, 705-711, 1995
  76. Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer RT, Vermynen J.  
Calin from *Hirudo medicinalis*, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters  
**Blood**, 85, 712-719, 1995
  77. Hoylaerts MF, Nuyts K, Peerlinck K, Deckmyn H, Vermynen J.  
Mechanism of ristocetin-induced binding of von Willebrand factor to glycoprotein Ib.  
**Biochem J**, 306, 453-463, 1995
  78. Blockmans D, Deckmyn H, Vermynen J  
Mechanisms of platelet activation.  
**Blood reviews**, 9, 143-156, 1995
  79. Kotzé HF, Badenhorst PN, Lamprecht S, Meiring M, van Wyk V, Nuyts K, Stassen JM, Vermynen J, Deckmyn H  
Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal antiplatelet glycoprotein IIb/IIIa antibody in a baboon model..  
**Thromb. Haemost** 74, 751-757, 1995
  80. Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Matthyssens G, Nyström A, Vermynen J  
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.  
**Thromb. Haemost.** 74, 655-659, 1995
  81. Matsuno H, Hoylaerts MF, Vermynen J, Deckmyn H  
Inhibition of integrin function prevents restenosis following vascular injury.  
**Folia Pharmacol Jpn** 106, 143-155, 1995
  82. Matsuno H, Stassen JM, Vermynen J, Deckmyn H  
Fast and reproducible vascular neointima formation in the hamster carotid artery. Effects of trapidil and captopril  
**Thromb. Haemost.** 74, 1591-1596, 1995
-

83. Blockmans D, Deckmyn H, De Vos R, Vermynen J  
Epinephrine induces a late thromboxane-dependent platelet shape change and enhances synergistically the shape change induced by other platelet agonists.  
**Platelets** 7, 35-42, 1996
84. Blockmans D, Deckmyn H, Van den Hove L, Vermynen J  
The effect of plasmin on platelet function.  
**Platelets** 7, 139-148, 1996

---

85. Azerad MA, Harsfalvi J, Deckmyn H, Vermynen J, Michaux JL, Hoylaerts MF  
Recirculated normal platelets adhere to surfaces coated with plasma from patients with immune thrombocytopenia.  
**Blood Coag. Fibrinol.** 8, 59-64, 1997
86. Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermynen J  
von Willebrand factor binds to native collagen VI primarily via its A1 domain.  
**Biochem.J.** 324, 185-191, 1997
87. Depraetere H, Wille C, Gansemans Y, Stanssens P, Lauwereys M, Baruch D, De Reys S, Deckmyn H.  
The integrin  $\alpha_2\beta_1$  (GPIa/IIa)-I-domain inhibits platelet-collagen interaction.  
**Thromb. Haemost.** 77, 981-985, 1997
88. Deckmyn H, Vanhoorelbeke K, Cauwenberghs N  
A platelet activating anti-glycoprotein Ib monoclonal antibody.  
**Blood** 90, 3807-3808, 1997

---

89. Stockmans F, Deberdt W, Bjerle P, Vermynen J, Nyström Å, Deckmyn H  
Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model  
**Thromb. Haemost.** 79, 222-227, 1998
90. Deckmyn H, Vanhoorelbeke K, Peerlinck K  
Acquired inhibitory or activating human antiplatelet antibodies.  
in "*Baillière's Clinical Haematology*" A.Eldor, JJ Michiels Eds 11, 343-359, 1998
91. Ajzenberg N, Depraetere H, Lacombe C, Deckmyn H, Baruch D.  
Distinct sequences of the GPIb-binding domain of von Willebrand factor involved in shear-induced platelet aggregation.  
**Platelets** 9, 151-153, 1998
92. Depraetere H, Ajzenberg N, Girma JP, Lacombe C, Meyer D, Deckmyn H, Baruch D  
Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand Factor.  
**Blood** 91, 3792-3799, 1998
93. Deroo S, Fournier P, Theisen D, Brons HC, Deckmyn H, Muller CP  
Phage displayed 6-mer mimotopes with a consensus proline absent in the minimized linear wild-type epitope.  
**Lett. Pept. Sci.** 5, 159-162, 1998
94. Depraetere H, Viaene A, Deroo S, Vauterin S, Deckmyn H  
Identification of peptides, selected by phage display technology, that inhibit von Willebrand Factor binding to collagen  
**Blood** 92, 4207-4211, 1998

---

95. Depraetere H, Kerekes A, Deckmyn H

The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and  $\alpha 2\beta 1$  (GPIa/IIa)-I-domain binding to collagen in a different manner.

**Thromb. Haemost.** 82, 1160-1163, 1999

96. Tornai I, Boda Z, Schlammadinger A, Juhasz A, Cauwenberghs N, Deckmyn H, Harsfalvi J.  
Acquired Bernard-Soulier Syndrome: A Case with Necrotizing Vasculitis and Thrombosis.  
**Haemostasis** 29, 229-236, 1999.

---

97. Vanhoorelbeke K\*, Cauwenberghs N\*, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H  
A new and reproducible vWF-RiCof assay  
**Thromb. Haemost.** 83, 107-113, 2000 \* contributed equally
98. Cauwenberghs N, Meiring M, Lamprecht S, Roodt JP, Vauterin S, Deckmyn H, Kotzé HF  
Antithrombotic effect of platelet glycoprotein Ib blocking monoclonal antibody Fab-fragments in a baboon model.  
**Arterioscl. Thromb. Vasc Biol**, 20, 1347-1353, 2000
99. Cauwenberghs N, Ajzenberg N, Vauterin S, Hoylaerts MF, Declerck PJ, Baruch D, Deckmyn H  
Characterization of murine anti-GPIb monoclonal antibodies that differentiate between shear-induced and rist/botrocetin-induced GPIb-vWF interaction.  
**Haemostasis** 30 (3), :139-148, 2000
100. Vanhoorelbeke K, van der Plas RM, Vandecasteele G, Vauterin S, Huizinga EG, Sixma JJ, Deckmyn H.  
Sequence alignment between vWF and peptides inhibiting the vWF-collagen interaction does not result in the identification of a collagen-binding site in vWF.  
**Thromb Haemost**, 84, 621-625, 2000
101. Cauwenberghs N, K. Vanhoorelbeke, S. Vauterin, Deckmyn H.  
Structural determinants within glycoprotein Ib $\alpha$  involved in its binding to von Willebrand factor  
**Platelets**, 11, 373-378, 2000

---

102. Cauwenberghs N, Schlammadinger A, Vauterin S, Cooper S, Descheemaeker G, Tornai I, Deckmyn H. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor.  
**Thromb Haemost** 85: 679-685, 2001
103. Viaene A, A. Crab, M. Meiring, D. Pritchard, H. Deckmyn  
Identification of a collagen-binding protein from *Necator americanus* by using a cDNA-expression phage display library.  
**J Parasitology**, 87: 619-25, 2001.
104. Ulrichs H, H. Depraetere, J. Harsfalvi, H. Deckmyn  
Selection of phages that inhibit von Willebrand Factor interaction with collagen under both static and flow conditions  
**Thromb Haemost**, 86, 630-635, 2001
105. Vanhoorelbeke K, A. Schlammadinger, JP. Delville, J. Handsaeme, G. Vandecasteele, S. Vauterin, O. Pradier, W. Wijns, H. Deckmyn  
Occurrence of the Asn45Ser mutation in the GPIX gene in a Belgian patient with Bernard-Soulier syndrome.  
**Platelets** 12: 114-120, 2001
106. Cauwenberghs N, K. Vanhoorelbeke, S. Vauterin, DF. Westra, G. Romo, E. Huizinga, J. Lopez, MC. Berndt, J. Harsfalvi, Deckmyn H.

Epitope mapping of inhibitory antibodies against platelet glycoprotein Iba reveals interaction between the leucine-rich repeat N-terminal and C-terminal domains of glycoprotein Iba  
**Blood** 98:652-660, 2001

107. Monnet E, H. Depraetere, C. Legrand, H. Deckmyn, F. Fauvel-Lafeve  
 A monoclonal antibody to platelet type III collagen-binding protein (TIIICBP) binds to blood and vascular cells, and inhibits platelet-vessel wall interactions.  
**Thromb Haemost**, 86, 694-635, 2001
108. Hoylaerts MF, Viaene A, Thys C, Deckmyn H, Vermynen J  
 Anti-vWF antibodies induce GPIIb/IIIa and FcγRII mediated platelet aggregation only at low shear stress.  
**J Thrombosis Thrombolysis**, 12, 249-262, 2001

---

109. Vanhoorelbeke K, Cauwenberghs N, Deckmyn H  
 A reliable vWF:RiCof ELISA method to differentiate between type I and type II von Willebrand disease. **Seminars in Thrombosis and Hemostasis**, 28 (2) Diagnosis and Management of Congenital von Willebrand Disease Guest Editors-JJ. Michiels and AH. Sutor, 2002
110. Wu D., M. Meiring, HF Kotzé, H Deckmyn, N. Cauwenberghs  
 Inhibition of platelet GPIb, GPIIb/IIIa or both by monoclonal antibodies, prevents arterial thrombus formation in baboons.  
**Arterioscl. Thromb. Vasc Biol**, 22, 323-328, 2002
111. Novak L, Deckmyn H, Damjanovich S, Harsfalvi J  
 Shear-dependent morphology of von Willebrand Factor bound to immobilized collagen  
**Blood** 99, 2070-2076, 2002
112. D Wu, K Vanhoorelbeke, N Cauwenberghs, M Meiring, H Depraetere, HF. Kotze, H Deckmyn  
 Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation in baboons  
**Blood** 99, 3623-3628, 2002 \* contributed equally  
 With editorial comment: "Does VWF bind collagen after all?" Evan Sadler  
**Blood** 99, 3491, 2002
113. Crab A, C. Pelicaen, W. Noppe, S. Vauterin, K. Vanhoorelbeke, H. Deckmyn  
 The parasitic hematophagous worm *Haemonchus contortus* inhibits human platelet aggregation and adhesion: partial purification of a platelet inhibitor.  
**Thromb. Haemost.** 87, 899-904, 2002

---

114. Fatturutto, Deckmyn H., Vanhoorelbeke K., Kotzé H.  
 A modified Folts model or the Folts model to evaluate new antithrombotics  
**Blood** 101, 782-783, 2003
115. Vanhoorelbeke K., Deckmyn H.  
 The role of vWF-collagen interaction in acute platelet thrombus formation.  
**Drugs of the Future**, 28, 61-67, 2003
116. Keuren JFW, H. Ulrichs, MAH. Feijge, K. Hamulyák, H Deckmyn, T Lindhout, JWM. Heemskerk  
 Involvement of glycoprotein Ib epitopes and integrin αIIbβ3 in platelets procoagulant activity of stirred plasma.  
**J Lab. Clin. Med.** 141, 350-358, 2003
117. Vanhoorelbeke K, Ulrichs H, Schoolmeester A, Deckmyn H

Inhibition of platelet adhesion as a new target for antithrombotic drugs.

**Current Drug Targets-Cardiovascular & Hematological Disorders** 3, 113-128, 2003

118. Vanhoorelbeke K, Depraetere H, Romijn RAP, Huizinga E, De Maeyer M, Deckmyn H  
A consensus tetra-peptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the VWF-collagen interaction  
**J. Biol.Chem** 278, 37815-37821, 2003
119. Ulrichts H, Vanhoorelbeke K, Vauterin S, Kroll H, Santoso S, Deckmyn H  
The platelet glycoprotein Ibalph HPA-2 polymorphism affects vWF binding, but not thrombin interaction.  
**Arterioscl. Thromb. Vasc Biol** 23:1302-1307, 2003
120. Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H  
Inhibition of platelet adhesion as a new target for antithrombotic drugs.  
**Current Drug Targets-Cardiovascular & Hematological Disorders** 3, 113-128, 2003

---

121. Vanhoorelbeke K, H Ulrichts, RA Romijn, EG Huizinga, H Deckmyn  
The GPIb alpha -thrombin interaction: far from crystal clear  
**Trends in Molecular Medicine** 10: 33-39 , 2004 IF 9.848
122. Siljander PR-M, Munnix ICA, Smethurst PA, Deckmyn H, Rankin A, Lindhout T, Ouwehand WH, Farndale RW, Heemskerk JWM  
Platelet receptor interplay regulates collagen-induced thrombus formation in flowing blood  
**Blood** 103, 1333-1341, 2004 IF 10.120  
with editorial comment: Platelet collagen receptors play molecular ping-pong .  
Mark L. Kahn **Blood** 103: 1180-1181, 2004.
123. Musaji A, Vanhoorelbeke K, Deckmyn H, Coutelier JP  
A New Model of Transient Strain-Dependent Autoimmune Thrombocytopenia in Mice Immunized with Rat Platelets  
**Experimental Hematology** 32: 87-94, 2004 IF 3.4
124. Schoolmeester A, Vanhoorelbeke K, Katsutani S, Depraetere H, Feys H, Heemskerk JMW, Hoylaerts MF, Deckmyn H.  
Monoclonal antibody IAC-1 is specific for activated integrin alpha2beta1 and binds to amino acid 199-201 of the integrin alpha2 I-domain.,  
**Blood** 104: 390-396, 2004 IF 10.120  
with editorial comment: Dotting the I of an I-domain Joel S Bennett  
**Blood** 104: 299-300, 2004
125. Ulrichts H, K. Vanhoorelbeke, G. Vandewalle, S. Katsutani, S. De Meyer, S. Staelens, H. Deckmyn  
New approaches for antithrombotic antiplatelet therapies"  
**Current Medicinal Chemistry** 11, 2261-2273, 2004 IF 4.409
126. JM Stassen, J Arnout, H Deckmyn  
The hemostatic system  
**Current Medicinal Chemistry**, 11, 2273-2286, 2004 IF 4.409
127. H. Deckmyn, H. Ulrichts, G. Vandewalle, K. Vanhoorelbeke  
Platelet antigens and their function  
**Vox sanguinis** 87 Suppl 2:105-11, 2004 IF 2.1
128. Ulrichts H., Harsfalvi J., Bene L., Matko J., Vermynen J., Ajzenberg N., Baruch D., Deckmyn H., Tornai I.,  
A monoclonal antibody directed against the N-terminal end of human von Willebrand Factor subunit,

induces type 2B-like alterations

**J. Thromb Haemost** 2: 1622-1628, 2004

129. K. Vanhoorelbeke, H. Deckmyn  
Inhibitie van von Willebrand Factor binding aan collageen als antitrombotische strategie  
**Bloedvaten, Hart en Longen** 9, 192-195, 2004
  - 129bis. K. Vanhoorelbeke, H. Deckmyn  
Stratégie antithrombotique via une inhibition de la liaison du fVW au collagène  
**Vaisseaux, Coeur et Poumons** 9, 192-195, 2004
  130. M Hellings, Y Engelborghs, H Deckmyn, K Vanhoorelbeke, ME Schiphorst, JW Akkerman, M De Maeyer. Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain.  
**Proteins: structure, function and bioinformatics** 57, 596-601, 2004
  131. Lecut C\*, Schoolmeester A\*, Broers JLV, van Zandvoort MAMJ, Vanhoorelbeke K, Deckmyn H, Jandrot-Perrus M, Heemskerk JWM Roles of glycoproteins VI and Ib in integrin activation and thrombus formation on collagen under flow.  
**Arterioscler Thromb Vasc Biol.** 24:1727-1733, 2004. \* contributed equally IF 6.791
  132. W. Noppe, K. Vanhoorelbeke, IY Galaev, B Mattiasson, H Deckmyn  
Identification and application of lactoferrin-binding phages isolated from phage-displayed peptide libraries.  
**J Dairy Sci.** 87, 3247-3255, 2004 IF 1.9
  133. C Lecut, V Arocas, H Ulrichs, A Elbaz, J-L Villeval, J-J Lacapère, H Deckmyn, M Jandrot-Perrus  
Identification of residues within human GPVI involved in the binding to collagen: evidence for the existence of distinct binding sites  
**J. Biol. Chem.** 279, 52293-9, 2004 IF 6.482
  134. K. Vanhoorelbeke, H. Deckmyn  
Inhibitie van von Willebrand Factor binding aan collageen als antitrombotische strategie  
**Neuron** 9, 262-267, 2004
  135. K. Vanhoorelbeke, H. Deckmyn  
Stratégie antithrombotique via une inhibition de la liaison du facteur von Willebrand au collagène  
**Neurone** 9, 262-267, 2004
- 
136. Vanhoorelbeke K, Pareyn I, Hoylaerts MF, Arnout J, Deckmyn H  
Plasma glyocalicin as a source of GPIIb/IIIa in the von Willebrand factor ristocetin cofactor ELISA  
**Thromb. Haemost.** 93, 165-171, 2005
  137. Deckmyn H, Cauwenberghs N, Wu D, Depraetere H, Vanhoorelbeke K.  
Development of antibodies that interfere with the collagen-vWF-GPIIb axis as new antithrombotics  
**Verhandelingen van de Koninklijke Academie voor Geneeskunde van België** 67, 55-65, 2005
  138. G. Xu, H. Ulrichs, S. Vauterin, S. De Meyer, H. Deckmyn, M. Teng, L. Niu.  
How does agkicetin-C bind on platelet glycoprotein Iba1 and achieve its platelet effects.  
**Toxicon** 45, 561-570, 2005
  139. H. Ulrichs, K. Vanhoorelbeke, S. Vauterin, H. Deckmyn  
The functional self-association of von Willebrand Factor is modulated by a multiple domain interaction.  
**J. Thromb. Haemost.** 3, 552-61, 2005.

140. JFW Keuren, SJH Wielders, H Ulrichts, T Hackeng, H Deckmyn, JWM Heemskerk, E Bevers, T Lindhout Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through PAR-1  
**Arterioscler Thromb Vasc Biol.** 25:1499-505, 2005
  141. G. Vande Walle, ZS Mayer, E Illyés, J Baert, K Vanhoorelbeke, I Pareyn, H Deckmyn  
Two functional active conformations of the integrin alpha2 beta 1, depending on activation condition and cell type.  
**J Biol Chem** 2005;280:36873-82
  142. DL Hughes, P Stafford, S Hamia, IJ Harmer, A Schoolmeester, H Deckmyn, RW Farndale, WH Ouwehand, NA Watkins Platelet integrin alpha2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display.  
**Thromb. Haemost.** 94: 1318-26, 2005
- 
143. S Staelens, MA Hadders, S Vauterin, C Platteau, M De Maeyer, K Vanhoorelbeke, EG Huizinga, H Deckmyn Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain  
**J Biol Chem** 2006;281:2225-2231.
  144. Ulrichts H, Udvardy M, Vanhoorelbeke K, Lenting PJ, Pareyn I, Vandeputte N, Deckmyn H  
Shielding of the A1-domain by the amino-terminal domain (AA764-1035) of von Willebrand Factor modulates its interaction with platelet glycoprotein Ib-IX-V.  
**J. Biol. Chem** 2006; 281:4699-707.
  145. De Meyer SF, K Vanhoorelbeke, MK Chuah, I Pareyn, V Gillijns, RP Hebbel, D Collen, H Deckmyn, T VandenDriessche Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor  
**Blood** 2006 107: 4728-4736  
with editorial comment by RR Montgomery  
A package for VWD endothelial cells  
**Blood** 2006;107 4580-4581
  146. Schlammadinger A., Vanhoorelbeke K., Laszlo P, Berecky Z, Muszbek L, Deckmyn H., Boda Z.  
Von Willebrand Factor antigen latex immunoassays are affected to a different extent by rheumatoid factor  
**Clin Appl Thromb Hemost** 2006; 12, 242-3
  147. Feys HB, Liu F, Dong N, Pareyn I, Vandeputte N, Noppe W, Vauterin S, Ruan C, Deckmyn H, Vanhoorelbeke K ADAMTS13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences  
**J Thromb Haemost** 2006; 4: 955-962  
with commentary by B. Lämmle: A new tool to further explore the role of ADAMTS-13 in health and disease **J Thromb Haemost** 2006;4: 952-4
  148. Liu F, Feys HB, Dong N, Bai X, Vanhoorelbeke K, Deckmyn H, Ruan C  
Determination of the antigen and activity of ADAMTS13 in patients with thrombotic thrombocytopenic purpura and carriers.  
**Chinese Journal of Hematology - Zhonghua Xue Ye Xue Za Zhi.** 2006;27:154-7
  149. Noppe W, Plieva FM, Galaev IY, Vanhoorelbeke K, Mattiasson B, Deckmyn H  
Phages as affinity ligands for the direct purification of lactoferrin from defatted milk  
**J Chromatography A** 2006; 1101: 79-80
  150. Caron C, L Hilbert, K Vanhoorelbeke, H Deckmyn, J Goudemand, C Mazurier



Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ib alpha in an enzyme-linked immunosorbent assay-based : performances in patients with type 2B von Willebrand disease.

**Br J Haematol.** 2006;133:655-63

151. De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H  
Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.  
**Cardiovasc. Hematol. Disord Drug Targets** 2006; 6 (3): 191-207
152. Orr AW , MH Ginsberg, S Shattil, H Deckmyn, MA Schwartz  
Matrix-specific suppression of integrin activation in shear stress signalling  
**Mol Biol Cell** 2006;17(11):4686-4697
153. Fontayne A, Vanhoorelbeke K, Pareyn I, Cauwenberghs N, Ngo TH, Dejaeghere D, La Roche Y, Barbeaux P., Van Rompaey I, Meiring M, Lamprecht S, Roodt J, Stassen JM, Deckmyn H  
Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4  
**Thromb Haemost** 2006;96(5):671-84.
154. Deckmyn H, Vanhoorelbeke K  
"Inside Blood": When collagen meets VWF  
**Blood** 2006; 108, 3628
155. BA Badlou, G Spierenburg, H Ulrichts, H Deckmyn, WM Smid, JWN Akkerman  
Role of Glycoprotein Ibalpha in phagocytosis of platelets by macrophages  
**Transfusion** 2006;46:2090-2099.
156. Pontiggia L, B Steiner, H Ulrichts, H Deckmyn, M Forestier, JH Beer  
Platelet microparticle formation and thrombin generation under high shear is effectively suppressed by a monoclonal antibody against GPIb alpha.  
**Thromb Haemost** 2006;96:774-80

---

157. De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K.  
False positive results in chimeraplasty for von Willebrand Disease.  
**Thromb Res.** 2007;119:93-104.
158. Van de Walle GRAJ, A Schoolmeester, BF Iserbyt, JMEM Cosemans, JWM Heemskerk, MF Hoylaerts, A Nurden, K Vanhoorelbeke, H Deckmyn  
Activation of  $\alpha IIb\beta 3$  is a sufficient but also an imperative prerequisite for activation of  $\alpha 2\beta 1$  in platelets  
**Blood** 2007;109:595-602
159. Vanhoorelbeke K, H Ulrichts, G Van de Walle, A Fontayne, H Deckmyn  
Inhibition of platelet glycoprotein Ib and its antithrombotic potential  
**Current Pharmaceutical Design** 2007;13:2684-97.
- 162 SM Penz, AJ Reininger, O Toth, H Deckmyn, R Brand, W Siess  
Glycoprotein Iba inhibition and ADP receptor antagonists, but not aspirin reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques  
**Thromb Haemost** 2007; 97: 435-443
163. Szanto T, Schlammadinger A, Pareyn I, Vauterin S, Harsfalvi J, Deckmyn H, Vanhoorelbeke K  
Type 2B von Willebrand disease in seven individuals from three families: phenotypic and genotypic characterization  
**Thromb Haemost** 2007;98:251-4.

164. Szanto T, A Schlammadinger, S Staelens, SF De Meyer, K Freson, S Vauterin, J Harsfalvi, H Deckmyn, K Vanhoorelbeke  
The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand Factor for glycoprotein Ibalph  
**Thromb Haemost** 2007;98:178-85.
  165. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM  
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis  
**Br J Haematology** 2007; 138:534-40
  166. Fontayne A, De Maeyer B, De Maeyer M, Yamashita M, Matsushita T, Deckmyn H  
Paratope and epitope identification of the antithrombotic antibody 6B4 in complex with GPIIb/IIIa  
**J Biol Chem** 2007; 282:23517-24
  167. Noppe W, FM Plieva, K Vanhoorelbeke, H Deckmyn, M Tuncel, A Tuncel, IY Galaev, B Mattiasson  
Macroporous monolithic gels, cryogels, with immobilized phages from phage-display library as a new platform for fast development of affinity adsorbent capable of target capture from crude feeds  
**J Biotechnol** 2007;131:293-299
  168. De Meyer SF, Staelens S, Badenhorst PN, Pieters H, Lamprecht S, Roodt J, Janssens S, Meiring M, Vanhoorelbeke K, Bruwer A, Brown S, Deckmyn H.  
Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor - collagen interaction in baboons  
**Thromb Haemost** 2007;98:1343-9
  169. Deckmyn H, Staelens S, Fontayne A, De Meyer SF, Vanhoorelbeke K  
The collagen-von Willebrand Factor-GPIIb axis as new antithrombotic target  
**Internatl Rev Thromb** 2007; 2: 26-32
  170. Deckmyn H, Murata M  
Professional interview: The VWF-GPIIb axis as a therapeutic target  
**Internatl Rev Thromb** 2007; 2: 5-17
  171. Martin K, Borgel D, Lerolle N, Feys HB, Trinquart L, Vanhoorelbeke K, Deckmyn H, Legendre P, Diehl JL, Baruch D. Decreased a disintegrin-like and metalloprotease with thrombospondin (ADAMTS)-13 is associated with a poor prognosis in sepsis-induced organ failure.  
**Crit Care Med.** 2007;35:2375-82.
- 
172. Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H.  
Inherited traits affecting platelet function.  
**Blood Rev.** 2008;22:155-72.
  173. Cosemans J, I Munnix, B Iserbyt, H Deckmyn J Heemskerk  
Multiple ways to switch platelet integrins on and off  
**J Thromb Haemost** 2008;6, 1253-1261
  174. De Meyer SF, MK Chuah, T VandenDriessche, N Vandeputte, I Pareyn, I Petrus, H Deckmyn, K Vanhoorelbeke  
Restoration of von Willebrand factor function in a murine model of severe von Willebrand disease by gene transfer  
**Atheroscl Thromb Vasc Res** 2008;28:1621-1626
  175. De Meyer SF, K Vanhoorelbeke, K Broos, II Salles, H Deckmyn  
Antiplatelet drugs  
**Br J Haematol** 2008, 142, 515-528

176. Fontayne A, M Meiring, S Lamprecht, J Roodt, E Demarsin, P Barbeaux, H Deckmyn  
The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons  
**Thromb Haemost** 2008;100:670-7.
  177. Munnix ICA, K Gilio, PRM Siljander, N Raynal, MAH Feijge, TM Hackeng, H Deckmyn, PA Smethurst, RW Farndale, JWM Heemskerk  
Collagen-mimetic peptides mediate flow-dependent thrombus formation by high or low affinity binding of integrin  $\alpha 2\beta 1$  and glycoprotein VI  
**J Thromb Haemost** 2008; 6: 2132–2142.
- 
178. O'Connor MN, II Salles, NA Watkins, A Walker, SF Garner, CI Jones, IC Macaulay, M Steward, JJ Zwaginga, SL Bray, A Cvejic, F Dudbridge, B de Bono, AH Goodall, H Deckmyn, DL Stemple, WH Ouwehand on behalf of the Bloodomics Consortium  
Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins.  
**Blood** 2009; 113: 4754 - 4762  
with *Inside Blood*: AS Weyrich, GA Zimmerman, Comparative genomics: fishing nets hemostatic catch **Blood** 2009; 113: 4479 - 4480.
  179. Kleinschnitz C, SF De Meyer, T Schwarz, M Austinat, K Vanhoorelbeke, B Nieswandt, H Deckmyn, G Stoll  
Deficiency of von Willebrand factor protects mice from ischemic stroke  
**Blood** 2009, 113: 3600-3603
  180. De Meyer SF, Deckmyn H, Vanhoorelbeke K  
von Willebrand factor to the rescue  
**Blood** 2009 prepublished online March 24, 2009; DOI 10.1182/blood-2008-10-165621
  181. Vanhoorelbeke K, SF De Meyer, I Pareyn, C Melchior, S Plançon, C Margue, O Pradier, P Fondu, N Kieffer, TA Springer, H Deckmyn  
The novel S527F mutation in the integrin beta3 chain induces a high affinity  $\alpha IIb\beta 3$  receptor by hindering adoption of the bent conformation.  
**J Biol Chem** published March 27, 2009 as doi:10.1074/jbc.M809167200v1
  182. De Meyer SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K  
Von Willebrand factor: drug and drug target.  
**Cardiovasc Hematol Disord Drug Targets**. 2009;9:9-20.
  183. Heger M, Salles II, van Vuure W, Deckmyn H, Beek JF  
Fluorescent labeling of platelets with polyanionic fluorescein derivatives.  
**Anal. Quant. Cytol. Histol.**, in press
  184. Feys HB, Deckmyn H, Vanhoorelbeke K  
ADAMTS13 in health and disease  
**Haemostaseology** in press
  185. Heger M, Salles II, van Vuure W, Hamelers IH, de Kroon AI, Deckmyn H, Beek JF  
On the interaction of fluorophore-encapsulating PEGylated lecithin liposomes with hamster and human platelets.  
**Microvascular Research** 2009 Mar 9. [Epub ahead of print]
  186. Heger M, II Salles, AI de Kroon, H Deckmyn Platelets and PEGylated lecithin liposomes: when stealth is allegedly picked up on the radar (and eaten)  
**Microvascular Research** in press

187. Noppe W, Plieva F, Galaev IY, Deckmyn H, Mattiasson B  
Chromato-panning: an efficient new mode of identifying suitable ligands from phage display peptide libraries.  
**BMC Biotechnology 2009, 9:21**
188. Deschrijver T, Verwilt P, Broos K, Deckmyn H, Dehaen W, De Borggraeve W  
Synthesis and modifications of a small library of 1,4-benzodiazepin-3-ones towards potential inhibitors of the collagen-von Willebrand Factor interaction.  
**Tetrahedron** in press

### **Proceedings of congresses**      *Published in full*

1. Vermylen J, Defreyn G, Deckmyn H.  
Antiplatelet drugs: a pharmacological survey.  
**Progr. Pharmacol.** 4, 9-19, 1982.
2. Deckmyn H, Gresele P, Arnout J, Vermylen J.  
Thromboxane synthase inhibition and thromboxane antagonism.  
In: "**Zbornik V. Konferenca o ateroskerozi in arterijski trombozi.**" Keber D, Stegnar M, Eds., Ljubljana, 61-64, 1986.
3. Deckmyn H, Vermylen J.  
Antiplatelet therapy: a review.  
In: "**Zbornik V. Konferenca o ateroskerozi in arterijski trombozi.**" Keber D, Stegnar M, Eds., Ljubljana, 55-60, 1986.
4. Majerus PW, Connolly TM, Ross TS, Ishii H, Deckmyn H.  
The role of phosphoinositides in cell physiology.  
**Anderson Symposium on Fundamental Cancer Research**, 39, 157-163, 1987.

### **Chapters in books**

1. Van der Giessen W, Serruys P, Stoel I, Hugenholtz P, De Leeuw P, Van Vliet H, Deckmyn H, Vermylen J. Acute effect of cigarette smoking on cardiac prostaglandin synthesis and platelet behavior in patients with coronary heart disease.  
In: "**Adv. Prost. Thromb. leuk. Res.**, Vol.11", Samuelsson B, Paoletti R, Ramwell P, Eds., Raven Press, New York, 359-364, 1983
2. Deckmyn H, Gresele P, Arnout J, Vermylen J.  
Manipulation of pro- and antiaggregating prostaglandins: new antithrombotic strategies.  
In: "**Drugs affecting leukotrienes and other eicosanoid pathways.**" Samuelsson B, Berti F, Folco GC, Velo G, Eds., Plenum Publishing Company, London, England, 141-147, 1985.
3. Vermylen J, Deckmyn H, Gresele P, Arnout J.  
Antithrombotic potential of thromboxane synthase inhibitors: problems and possible solutions.  
In: "**Prostaglandins and other Eicosanoids in the Cardiovascular System.**" Schrör, Ed, Karger, Basel, 445-453, 1985.
4. Gresele P, Arnout J, Deckmyn H, Vermylen J.  
Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans.  
In: "**Adv. Prost. Thromb. Leuk. Res.**" vol. 17A, Samuelsson B, Paoletti R, Ramwell PW, Eds., Raven Press N.Y., 248-253, 1987.
5. Wilson DB, Connolly TM, Ross TM, Ishii H, Bross TE, Deckmyn H,

- Brass LF, Majerus PW.  
Phosphoinositide metabolism in human platelets.  
In: "**Adv. Prost. Thromb. Leuk. Res.**." vol. 17A,  
Samuelsson B, Paoletti R, Ramwell PW, Eds., Raven Press N.Y., 558-562, 1987.
6. Vermylen J, Gresele P, Arnout J, Deckmyn H.  
Thromboxane synthase inhibitors: ex vivo studies.  
In: "**Biology of Icosanoids.**" Lagarde M, Ed., Colloque INSERM 152, 383-388, 1987.
  7. Deckmyn H, Whiteley BJ, Majerus PW.  
Phosphatidylinositol phospholipase C.  
In: "**G-proteins.**", Birnbaumer L, Iyengar R, Eds., Academic Press, 429-452, 1990.
  8. Vermylen J, Deckmyn H.  
Antiplatelet agents: pharmacology and clinical use.  
In: "**Recent Adv. Blood Coag.**" Poller L, Ed., vol. 6, 125-144, 1993.
  9. Badenhorst PN, Kotzé HF, Lamprecht S, Meiring M, van Wyk V, Deckmyn H  
Dose-dependent inhibition of acute arterial thrombosis by monoclonal antibody (16N7C2) in a baboon model.  
in: "**Radiolabeled Blood Elements.**", ed.: Martin-Comin J, Plenum Press, NY, pp 343-347, 1994
  10. Badenhorst PN, Kotzé HF, Lamprecht S, Meiring M, van Wyk V, Deckmyn H  
Dose-dependent inhibition of acute arterial thrombosis by monoclonal antibody (16N7C2) in a baboon model.  
in: "**Radiolabeled Blood Elements.**", ed.: Martin-Comin J, Plenum Press, NY, pp 343-347, 1994
  11. Deckmyn H, Vanhoorelbeke K, Peerlinck K  
Functional human antiplatelet antibodies.  
In: "**Acquired Disorders of Haemostasis: Pathophysiology, Clinical Practice and Basic Research.**" Eldor A, Michiels JJ Eds, "Bailliere's Best Practice and Research in Clinical Haematology" 11, 343-359, 1998
  12. Deckmyn H, Vanhoorelbeke K., Ulrichs H., Schoolmeester A., Staelens S., De Meyer S.  
Amplification loops and signal transduction pathways  
in "**Thrombosis -Fundamental and Clinical Aspects**" ed. J. Arnout, G. de Gaetano, M. Hoylaerts, K. Peerlinck, C. Van Geet, R. Verhaeghe  
Leuven University Press, pp. 75-91, 2003
  13. Deckmyn H, Staelens S, Fontayne A, De Meyer SF, Vanhoorelbeke K  
Inhibition of the collagen-von Willebrand factor - GPIb axis as a new antithrombotic strategy  
in "**Proc European VWF VWD workshop**", University press Antwerp, ed. JJ Michiels, 2008, 22-26
  14. De Meyer S, Deckmyn H, Vanhoorelbeke K  
Towards gene therapy for von Willebrand disease  
in "**Proc European VWF VWD workshop**", University press Antwerp, ed. JJ Michiels, 2008, 34-36
  15. Feys HB, Deckmyn H, Vanhoorelbeke K  
ADAMTS13 in health and disease  
in "**Proc European VWF VWD workshop**", University press Antwerp, ed. JJ Michiels, 2008, 176-9
  16. Salles II, MN O'Connor, DC Thijssen-Timmer, K Broos, H Deckmyn  
Platelet Functional Genomics  
In "**Platelet Proteomics: Principles, Analysis and Applications**,"  
eds. A Garcia, Y Senis. J Wiley & Sons, Inc, NJ. 2009